{"id":"NCT04074928","sponsor":"Seqirus","briefTitle":"Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects","officialTitle":"A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) and a United States Licensed Quadrivalent Influenza Virus Vaccine (QIV) in Healthy Subjects 6 Months Through 47 Months","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-06","primaryCompletion":"2020-09-03","completion":"2020-09-03","firstPosted":"2019-08-30","resultsPosted":"2022-01-12","lastUpdate":"2022-01-12"},"enrollment":2414,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza","Human","Virus Diseases"],"interventions":[{"type":"BIOLOGICAL","name":"QIVc","otherNames":["Flucelvax Quadrivalent"]},{"type":"BIOLOGICAL","name":"Comparator QIV","otherNames":["Afluria Quadrivalent"]}],"arms":[{"label":"QIVc","type":"EXPERIMENTAL"},{"label":"Comparator QIV","type":"ACTIVE_COMPARATOR"}],"summary":"This phase 3 clinical study is a randomized, observer-blind, comparator-controlled, multicenter study of QIVc versus a US-licensed comparator QIV in children 6 months through 47 months of age. The purpose of this study is to demonstrate that vaccination with QIVc elicits an immune response that is noninferior to that of a US-licensed comparator QIV containing the same virus strains, in children 6 months through 47 months of age.","primaryOutcome":{"measure":"Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HAI) Assay Using Cell-derived Target Viruses","timeFrame":"Day 29 for previously vaccinated subjects; Day 57 for not previously vaccinated subjects","effectByArm":[{"arm":"QIVc","deltaMin":78,"sd":null},{"arm":"Comparator QIV","deltaMin":57.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":47,"countries":["United States"]},"refs":{"pmids":["36214072"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":1597},"commonTop":["Injection site tenderness","Irritability","Sleepiness","Injection site erythema","Change of eating habits"]}}